Status:
UNKNOWN
ARAPS Study on Accelerated Liver Regeneration
Lead Sponsor:
University of Aarhus
Collaborating Sponsors:
Rigshospitalet, Denmark
Conditions:
Liver Regeneration
Liver Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Liver resection is the golden standard in the treatment of hepatic malignancies. The size and function of the remnant liver is a major concern. If the future liver remnant (FLR) is below 30 % of the i...
Detailed Description
Curative intent liver resection is the gold standard for treatment of hepatic malignancies, including metastases from colorectal cancer (CRLM), but liver resection can only be performed if future live...
Eligibility Criteria
Inclusion
- Patients with Colorectal liver metastasis; initially considered unresectable or borderline resectable due to an expected postoperative FLR volume of \<30 %
- Extrahepatic metastatic disease is not an exclusion criteria if it can be treated with curative intent
Exclusion
- Liver cirrhosis
- Significant comorbidity rendering subjects unsuitable for major surgery
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04107324
Start Date
January 1 2020
End Date
May 1 2023
Last Update
January 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital
Aarhus, Denmark, 8200